NRx Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NRXP research report →
Range $2 – $2
Price Chart
About the company
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19.
- CEO
- Jonathan C. Javitt
- IPO
- 2017
- Employees
- 29
- HQ
- Wilmington, DE, US
Get TickerSpark's AI analysis on NRXP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $95.31M
- P/E
- -4.87
- Fwd P/E
- 71.67
- PEG
- -0.02
- P/S
- 26.22
- P/B
- -55.43
- EV/EBITDA
- -5.27
- Div Yield
- 0.00%
- Gross Margin
- 29.92%
- Op Margin
- -556.53%
- Net Margin
- -458.48%
- ROE
- 247.77%
- ROIC
- 2380.16%
Latest fiscal year · YoY change
- Revenue
- $1.23M+0.0%
- Gross Profit
- $720.00K+14500.0%
- Op Income
- $-16,224,000
- Net Income
- $-28,622,000-13.9%
- EPS
- $-1.34+43.9%
- OCF Growth
- -32.7%
- FCF Growth
- -32.7%
- 52W High
- $5.06
- 52W Low
- $1.62
- 50D MA
- $2.75
- 200D MA
- $2.98
- Beta
- 2.07
- RSI (14)
- 51
- Avg Volume
- 1.06M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
NRx said it has crossed into commercialization, with its first FDA approval, early patient revenue growth, and a cash position that management says supports ongoing launches and pipeline work.· November 17, 2026
- Third-quarter patient revenue rose to $1.2 million from $0.2 million a year ago, while net loss narrowed to $2.2 million, or $0.05 per share.
- The company said FDA approved its abbreviated new drug application for preservative-free ketamine on October 29, and that it received its first order from a customer.
- NRx ended the quarter with about $20 million in cash and cash equivalents and said it has no convertible debt.
- Management outlined four operating divisions: sterile injectables, HOPE Therapeutics clinics, NRx Defense Systems, and GeNeuro.
- The company said it plans to submit a rolling NDA for NRX-100 by year-end and expects NRX-200 to enter pharmacokinetic testing in early 2027.
For the third quarter ended September 30, 2026, NRx reported net patient revenue of $1.2 million versus $0.2 million in the third quarter of 2025. Loss from operations was $8.1 million, compared with $4 million from the prior quarter, and net loss was $2.2 million, or $0.05 per share, versus $5.9 million, or $0.27 per share, in the prior comparable quarter. For the 9 months ended September 30, 2026, net loss was $20.1 million versus $29 million a year ago, and loss from operations was $19.4 million versus $11.6 million. Cash and cash equivalents were about $19.8 million at September 30, 2026, up from $7.8 million at December 31, 2025, driven mainly by a public offering with gross proceeds of more than $22 million. Looking ahead, management said current cash, recent product revenue, growing clinic revenue, and the ATM facility should support operations for the foreseeable future.
Jonathan Javitt framed the quarter as a transition from development-stage biotech to a commercial pharmaceutical company. He emphasized the first FDA approval, the launch of a sales force, and the company’s move into four divisions that he said can be financed in nondilutive ways and potentially become profitable on their own. His tone was highly optimistic and expansive, centered on manufacturing advantages, pipeline breadth, and the idea that NRx can build a durable business around near-term revenue while advancing longer-term drug assets.
Michael Abrams focused on the financial results and liquidity. He cited $1.2 million of net patient revenue, the $2.2 million net loss for the quarter, and the $19.8 million cash balance at quarter-end, noting that cash increased largely because of a public offering with gross proceeds of more than $22 million. He said the current cash position, recent launch revenue, expected clinic growth, and use of the ATM facility should be enough to fund operations for the foreseeable future.
Analysts pressed on the commercialization strategy for preservative-free ketamine, the expected market share, and how the new NRX-200 subcutaneous program would be developed. Management said the main market is hospitals and hospital outpatient departments, not psychiatry clinics, and said it would be happy with 20% to 30% share but sees a possible larger opportunity if a citizen petition changes the market. Questions on NRX-101 focused on whether lurasidone adds value and how much FDA has already reviewed; management said FDA has looked at the data in detail and asked for comparisons between PHQ-9 and MADRS, which NRx is addressing. On GeNeuro, management said GNK-301 targets a biologically defined ALS subgroup that they believe covers most ALS patients, and that a Science Day is planned for early December.
The strongest bull case from the call is that NRx says it has crossed from pipeline story to revenue-generating company, with a first FDA approval, a first customer order, and clinic revenue already flowing. Management also argued it has multiple shots on goal: sterile injectables, NRX-100 approval pathways, NRX-200, DARPA-funded work, and GeNeuro assets, with several programs potentially supported by nondilutive funding.
The main bear case is that much of the story still depends on execution across multiple highly ambitious programs, including regulatory approvals, commercialization, and clinical readouts that are still ahead. Revenue remains small relative to losses, and management is assuming future growth from several uncertain sources, including the ketamine market, FDA pathways for NRX-100, and financing for the newer divisions. The company also highlighted competitive and manufacturing hurdles for would-be rivals, which underscores that the product opportunity is still new and not yet broadly proven in the market.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 86.4%
- Shares Outstanding
- 44.33M
- Float Shares
- 38.31M
of shares held by institutions
52 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| B Group, Inc. | 4.28M | ▲ 185.43K |
| Vanguard Capital Management LLC | 1.79M | ▲ 171.13K |
| Ameriprise Financial Inc | 1.42M | ▲ 486.48K |
| Balyasny Asset Management L.P. | 1.05M | ▲ 159.34K |
| Marshall Wace, Llp | 995.17K | ▲ 800.59K |
| Advisorshares Investments LLC | 805.07K | ▲ 146.05K |
| Citadel Advisors LLC | 746.63K | ▲ 66.59K |
| Vanguard Group Inc | 729.84K | ▲ 194.89K |
| Commonwealth Equity Services, LLC | 590.77K | ▲ 136.35K |
| Geode Capital Management, LLC | 446.46K | ▲ 131.80K |
| Ubs Group AG | 379.19K | ▼ 43.92K |
| Vanguard Fiduciary Trust Co | 259.80K | ▲ 77.08K |
Held by 29 ETFs
Biggest fund positions in NRXP by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 28, 26 | ABRAMS MICHAEL S | other | 75,000 |
| Jul 28, 26 | Javitt Jonathan C | other | 150,000 |
| Jan 27, 26 | Casper Joseph Michael | other | 100,000 |
| Jan 27, 26 | Casper Joseph Michael | other | 0 |
| Apr 9, 25 | Javitt Jonathan C | other | 125,000 |
| Apr 9, 25 | McBride Dennis | other | 25,000 |
| Apr 9, 25 | Hurvitz Chaim | other | 25,000 |
| Apr 9, 25 | Flynn Patrick John | other | 50,000 |
| Aug 18, 25 | B Group, Inc. | other | 0 |
| Feb 7, 25 | ABRAMS MICHAEL S | other | 50,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NRXP coverage
Recent articles, reports, and earnings notes.
No research on NRXP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NRXP report →NRx Pharmaceuticals, Inc. (NRXP) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 17
What NRx Pharmaceuticals (NRXP) Said on Its Q3 Earnings Call
marketbeat.com · Nov 17
NRx Pharmaceuticals (Nasdaq: NRXP) Reports Third Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com · Nov 17
NRx Pharmaceuticals, Inc. (NRXP) Reports Q3 Loss, Misses Revenue Estimates
zacks.com · Nov 16
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2026 Financial Results and Provide Corporate Update
globenewswire.com · Nov 12
NRx Pharmaceuticals Begins Selling U.S.-Made, Preservative-Free Ketamine Amid Long-Running Shortage
globenewswire.com · Nov 11
NRx Pharmaceuticals (NASDAQ:NRXP) versus TherapeuticsMD (NASDAQ:TXMD) Head-To-Head Contrast
defenseworld.net · Nov 6
NRx Pharmaceuticals, Inc. (NRXP) Discusses FDA Approval of Preservative-Free Ketamine Transcript
seekingalpha.com · Oct 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.